How to Get Vyvanse in Missouri

Who Can Prescribe Vyvanse in Missouri

Any Missouri-licensed prescriber with DEA Schedule II authority can write a Vyvanse prescription. That includes physicians (MD and DO), advanced practice registered nurses (APRNs) with prescriptive authority, and physician assistants operating under a collaborative practice agreement.

Missouri revised statutes (RSMo 334.735 and 334.104) grant APRNs and PAs the ability to prescribe controlled substances, including Schedule II stimulants, provided they maintain a collaborative practice arrangement with a supervising physician. In practice, most telehealth platforms and psychiatric clinics in Missouri staff at least one MD or DO who reviews ADHD evaluations before prescriptions are issued. The prescriber must hold both a valid Missouri license and an active DEA registration with the state address on file.

PAs in Missouri gained Schedule II prescriptive authority in 2017. APRNs have held this authority since 2007 under specific supervision rules. If you see an NP or PA for your ADHD evaluation, their collaborating physician may co-sign the first prescription, depending on the practice's internal policy.

Telehealth Prescribing Rules in Missouri

Missouri allows Schedule II controlled substances to be prescribed via telehealth after a qualifying clinical evaluation. This is legal. The prescriber must document the assessment in the patient's medical record and comply with the same standard of care as an in-person visit.

Missouri's telehealth parity law (RSMo 191.1145) requires insurers to cover telehealth services at the same rate as in-person care. The Ryan Haight Online Pharmacy Consumer Protection Act, a federal statute enforced by the DEA, historically required one in-person visit before a Schedule II telehealth prescription. Temporary flexibilities introduced during the COVID-19 public health emergency were extended through DEA rulemaking, and prescribers using a DEA-registered telehealth platform may initiate Vyvanse prescriptions without a prior in-person visit under current rules.

A typical Missouri telehealth ADHD evaluation includes a structured symptom interview (often based on the DSM-5 criteria and the Adult ADHD Self-Report Scale), review of childhood symptoms, screening for comorbid anxiety or depression, and a substance use history. The visit usually lasts 45 to 60 minutes for an initial assessment.

Missouri does not require the originating site (the patient's location) to be a clinical facility. You can complete the visit from your home. The prescriber sends an electronic prescription directly to a Missouri pharmacy using EPCS (electronic prescribing for controlled substances), which Missouri requires for Schedule II drugs as of 2021.

What Labs and Evaluations Are Needed Before Starting Vyvanse

No specific blood test is FDA-mandated before initiating lisdexamfetamine. However, clinicians routinely order baseline labs and vitals to rule out contraindications and establish monitoring benchmarks.

Most prescribers in Missouri will check resting heart rate and blood pressure at baseline. Lisdexamfetamine is a prodrug of dextroamphetamine, and sympathomimetic stimulants raise both metrics. The Vyvanse prescribing information warns against use in patients with known structural cardiac abnormalities, cardiomyopathy, serious heart rhythm abnormalities, or coronary artery disease. Patients with a family history of sudden cardiac death or personal history of syncope may be referred for an EKG before starting treatment.

A complete metabolic panel or CBC is not universally required, but some clinicians order one to rule out thyroid dysfunction (which mimics ADHD symptoms) or anemia-related fatigue. A urine drug screen is standard at many practices, especially for new patients, to screen for active substance use that could complicate stimulant therapy.

Wigal et al. (2017) evaluated lisdexamfetamine dose optimization in adults with ADHD (N=142) and found that doses between 30 mg and 70 mg improved ADHD Rating Scale scores by a mean of 16.2 points versus 6.2 for placebo over a 4-week forced-dose titration. Baseline vital sign monitoring was a protocol requirement in that trial, reflecting real-world clinical practice.

Your prescriber will also review your current medication list. Monoamine oxidase inhibitors (MAOIs) are contraindicated with lisdexamfetamine. Concomitant use of serotonergic drugs raises the risk of serotonin syndrome, and acidifying or alkalinizing agents can alter amphetamine excretion.

Missouri Medicaid and Insurance Coverage

Missouri Medicaid (MO HealthNet) does not cover Vyvanse for ADHD or binge eating disorder on its preferred drug list. This is a significant barrier for the roughly 1.1 million Missouri residents enrolled in Medicaid.

Patients on MO HealthNet who need stimulant treatment for ADHD are typically steered toward generic alternatives: mixed amphetamine salts (generic Adderall), methylphenidate, or dextroamphetamine. If a prescriber documents clinical necessity for Vyvanse specifically (e.g., prior treatment failure with two or more generic stimulants, history of stimulant misuse favoring the prodrug mechanism), a non-preferred drug authorization can be submitted. Approval rates for these exceptions are low without strong documentation.

Commercial insurance plans operating in Missouri generally cover Vyvanse, though most require prior authorization. The PA process typically asks for:

• Confirmed DSM-5 ADHD or BED diagnosis
• Documentation of prior trial and failure (or intolerance) of at least one preferred stimulant
• Prescriber's rationale for Vyvanse over generic options

The American Academy of Family Physicians guidelines recommend starting with the lowest effective dose and titrating based on response and tolerability, a stepped approach that aligns with most insurers' prior authorization criteria.

Takeda offers the Vyvanse Savings Program, which reduces out-of-pocket costs to as low as $30 per month for commercially insured patients. Uninsured patients may qualify for Takeda's patient assistance program (Help at Hand), which provides the medication at no cost to those below 250% of the federal poverty level.

How Long Until You Receive Vyvanse in Missouri

From first appointment to medication in hand, most Missouri patients can expect a timeline of 3 to 10 business days. Here is a realistic breakdown.

The initial evaluation (telehealth or in-person) takes one appointment. If the prescriber diagnoses ADHD and determines Vyvanse is appropriate, they send the EPCS prescription the same day. For patients whose insurance does not require prior authorization, the pharmacy can fill the prescription within 24 to 48 hours, depending on stock.

Prior authorization adds 1 to 5 business days. Missouri law (RSMo 376.383) requires commercial insurers to respond to a PA request within 48 hours for non-urgent requests. If the PA is denied, the prescriber can file a peer-to-peer appeal, which adds another 2 to 5 days.

Pharmacies in major Missouri metro areas (St. Louis, Kansas City, Springfield, Columbia) generally keep Vyvanse in stock. Smaller rural pharmacies may need to order it, which adds 1 to 2 business days. Because Vyvanse is a Schedule II controlled substance, pharmacies cannot transfer prescriptions between locations. If your pharmacy is out of stock, the prescriber must send a new prescription to an alternative pharmacy.

"A Schedule II prescription in Missouri cannot be called in by phone. It must be transmitted electronically via EPCS or provided as a written prescription with a wet signature," per Missouri Board of Pharmacy regulations. Missouri was among the states that adopted mandatory EPCS to reduce prescription fraud and simplify the dispensing process.

Transferring a Vyvanse Prescription to Missouri

You cannot transfer an existing Schedule II prescription from another state to a Missouri pharmacy. Federal law prohibits the transfer of Schedule II controlled substance prescriptions between pharmacies entirely.

If you are relocating to Missouri from another state, you need a new prescription from a Missouri-licensed prescriber. The practical approach: bring your medical records, including your prior ADHD evaluation, treatment history, and current dose. A Missouri prescriber can use these records to continue your existing regimen without repeating the full diagnostic workup.

Some telehealth platforms that operate in multiple states can support a faster transition. If your out-of-state prescriber also holds a Missouri license, they can write a new Missouri-origin prescription using EPCS. Otherwise, plan for a new evaluation with a Missouri-licensed provider.

Your previous prescriber should send records directly to your new Missouri provider. Under HIPAA, they must comply with a records release request within 30 days, though most clinics process them in 5 to 10 business days. Bring a copy yourself if possible to avoid delays.

503A Compounding Pharmacies in Missouri

Missouri has licensed 503A compounding pharmacies that can prepare custom formulations of certain medications. However, lisdexamfetamine is a Schedule II controlled substance and a branded prodrug with no commercially available API (active pharmaceutical ingredient) for compounding.

503A pharmacies in Missouri are regulated by the Missouri Board of Pharmacy and must compound from bulk drug substances that appear in the FDA's list of approved APIs or the USP compounding standards. Lisdexamfetamine is not available as a bulk compounding ingredient from standard chemical suppliers. The prodrug design (lysine + dextroamphetamine) is specific to Takeda's formulation.

In practice, if a patient cannot swallow the capsule, the FDA-approved prescribing information permits opening the capsule and dissolving the contents in water. This is the recommended approach rather than seeking a compounded formulation. Takeda also manufactures a chewable tablet form (Vyvanse chewable, 10 mg to 60 mg) that was FDA-approved in 2017.

Prior Authorization Documentation in Missouri

Missouri commercial insurers and managed Medicaid plans typically require specific documentation to approve a Vyvanse prior authorization. Having these items ready before your prescriber submits the PA request can prevent delays.

The standard documentation package includes:

• DSM-5 diagnostic criteria met, with specific symptoms documented
• ADHD rating scale scores (such as the ASRS v1.1 or Conners Adult ADHD Rating Scale)
• List of previously trialed medications, including drug name, dose, duration, and reason for discontinuation (failure, partial response, or adverse effect)
• Clinical rationale for Vyvanse over generic alternatives. The prodrug mechanism of lisdexamfetamine, which requires enzymatic cleavage in the GI tract to release active dextroamphetamine, produces a smoother pharmacokinetic profile and lower abuse potential compared to immediate-release amphetamine formulations, per FDA labeling
• If the patient has binge eating disorder, documentation should include BED diagnostic criteria, binge episode frequency, and prior behavioral therapy attempts

The Endocrine Society and AACE guidelines do not directly govern ADHD treatment, but for patients with comorbid obesity and BED, cross-referencing these guidelines can strengthen the PA argument. A 2019 analysis in the Journal of Clinical Psychiatry found that lisdexamfetamine reduced binge eating days per week from 4.5 to 1.1 versus 3.3 for placebo over 12 weeks (McElroy et al., 2016; N=773).

"The clinical team should document why the specific pharmacokinetic properties of lisdexamfetamine are medically necessary for this patient, not merely preferred," as stated in the Missouri Division of Medical Services PA guideline.

Cost Without Insurance in Missouri

A 30-day supply of brand-name Vyvanse in Missouri costs approximately $350 to $450 without insurance, depending on the pharmacy and dose strength. Generic lisdexamfetamine became available in August 2023, and generic versions from manufacturers including Teva and Alvogen are now stocked at most Missouri pharmacies.

Generic lisdexamfetamine typically costs $30 to $80 for a 30-day supply at major retail pharmacies (CVS, Walgreens, Walmart) using a GoodRx or similar discount coupon. This price drop has substantially improved access for uninsured and underinsured Missouri patients.

The Vyvanse Savings Card (for commercially insured patients) reduces copays to as low as $30 per 30-day fill, with a maximum annual benefit. Takeda's Help at Hand patient assistance program provides brand-name Vyvanse at no cost for qualifying patients earning below 250% FPL (approximately $37,650 for a single-person household in 2026).

Missouri also has the Show-Me Rx program, a state-sponsored prescription assistance initiative that helps low-income residents access discounted medications. Eligibility and formulary vary, so patients should verify lisdexamfetamine coverage before enrolling.

Refills for Schedule II medications in Missouri can be written for up to a 90-day supply per prescription, though the prescriber must issue a new prescription each time (no refills are permitted on Schedule II drugs under federal law). Some prescribers write three separate 30-day prescriptions with "do not fill before" dates, which Missouri pharmacies can accept per DEA policy.